MONTREAL — The landscape of retina care is undergoing a significant transformation as new data confirms the long-term efficacy and safety of the ranibizumab port delivery system (PDS; Susvimo) for patients suffering from diabetic macular edema (DME). According to updated findings from the pivotal PAGODA trial, patients utilizing the continuous-delivery device maintained substantial improvements in both visual acuity and retinal anatomy for up to four years, marking a potential paradigm shift in how clinicians manage chronic diabetic eye disease.
The findings, presented by Luke Lindsell, OD, MD, of the Cincinnati Eye Institute, at the annual meeting of the American Society of Retina Specialists, suggest that the PDS not only preserves vision but significantly reduces the heavy treatment burden typically associated with frequent, recurring intravitreal injections.
Main Facts: A Breakthrough in Continuous Delivery
At the core of the PDS technology is the concept of sustained release. Unlike traditional therapies that require monthly or bi-monthly injections, the PDS is a surgically implanted device that provides a continuous, steady-state delivery of ranibizumab—a potent anti-VEGF agent—directly into the vitreous.
The PAGODA trial, which evaluated the 100 mg/mL PDS with a refill interval of 24 weeks, has now provided 208 weeks of follow-up data. The results indicate that patients initially assigned to the PDS achieved a 9.4-letter improvement from baseline in best-corrected visual acuity (BCVA) and a clinically significant 211-µm decrease in central subfield thickness (CST). Perhaps most importantly, approximately half of the patient cohort demonstrated at least a two-step improvement on the Diabetic Retinopathy Severity Scale (DRSS), a key indicator of disease progression.
Perhaps the most compelling statistic for clinicians is that 95% of patients in the study required no supplemental anti-VEGF therapy between the six-month device refill intervals. This reliability underscores the potential for the PDS to move the field away from "reactive" treatment—where therapy is provided only when disease flares up—toward a "proactive," continuous-management model.
Chronology of the PAGODA Trial
The path to these long-term results was carefully structured to ensure both safety and scientific rigor.
- Initial Randomization: The trial enrolled 634 patients, with a 3:2 randomization ratio, comparing the PDS to the traditional standard of care: monthly intravitreal injections of ranibizumab. All participants in the trial had prior experience with intravitreal injections, establishing a baseline of familiarity with standard treatment burdens.
- The 64-Week Milestone: At 64 weeks, the study met its primary endpoint for noninferiority regarding BCVA. Following this milestone, patients in the control group—who had been receiving monthly injections—were transitioned to the PDS.
- The Transition Period: Data from these "switch" patients proved vital. Those who moved from monthly injections to the PDS at the 64-week mark showed improvements in BCVA, CST, and DRSS that were remarkably similar to those who received the device at the start of the study.
- Long-Term Follow-Up (208 Weeks): The extended follow-up period confirmed that while patients experienced a transient, minor decrease in BCVA immediately following the surgical insertion of the device, vision recovered quickly and remained stable for the duration of the four-year study.
Supporting Data and Efficacy Metrics
The strength of the PAGODA trial lies in its consistency across multiple metrics. At the 208-week mark, 75.4% of patients in the original PDS arm and 72.2% in the switch group achieved 20/40 vision or better. This is a critical threshold, as it represents driving-level vision—a vital quality-of-life component for the predominantly working-age population afflicted by DME.
The Biological Stability Question
Beyond the clinical efficacy, the trial provided an unexpected, yet critical, answer regarding the storage of biological agents. Traditionally, ophthalmologists have been constrained by the strict temperature requirements for storing anti-VEGF biologics. However, observations from the PAGODA trial have been eye-opening.
"The data I like most is that you can store a biologic at body temperature for months, even over a year, and it’s still biologically active," noted Charles Wykoff, MD, PhD, of Retina Consultants of Texas. This finding may simplify logistics and expand the therapeutic window for future drug-delivery implants, suggesting that biological integrity can be maintained within the ocular environment far longer than previously theorized.
Official Responses and Clinical Perspectives
The medical community remains cautiously optimistic, balancing the clear benefits of the device with the inherent risks of surgical implantation.
Dr. Lindsell, an early adopter of the technology, noted that his clinical experience mirrors the trial results. "I have a lot of patients that I’ve moved out of the original clinical trials who are receiving fellow-eye treatment with standard of care, and all of them have asked to have the device put in their fellow eye," he reported. He emphasized that for patients with irregular schedules or those who struggle to maintain a monthly injection cadence, the PDS is an ideal solution.
"I have had patients who just randomly did not come back, and I see them 10 months later and they’re still dry," Lindsell added, highlighting the "safety net" the device provides for patients who might otherwise fall out of the healthcare system.
However, Dr. Wykoff offered a more measured perspective. While he acknowledges that patients overwhelmingly prefer the PDS over frequent injections—citing survey data where 80% to 90% of patients preferred the six-month interval—he uses the device more sparingly.
"I do talk to patients about it, but there is a risk," Wykoff explained. "You’re raising the conjunctiva, and the chronic movement of the eyelid across that zone does, I think, create a long-term risk for potential exposure." He noted that the presence of a "black box" warning on the package insert remains a point of serious discussion during the informed consent process with his patients.
Implications: The Future of Retina Care
The PDS represents one piece of a much larger puzzle in the treatment of diabetic eye disease. As Dr. Wykoff noted, the field is currently grappling with a "conundrum": diabetic eye disease is often treated only after significant progression or the development of adverse events.
A Multi-Modal Future
The success of the PDS suggests that we are moving toward a future defined by:
- Reduced Treatment Burden: Moving away from the "injection fatigue" that currently plagues patients and leads to non-adherence.
- Technological Diversity: The PDS is not expected to be a "silver bullet." Experts anticipate a future involving a mix of technologies, including implants embedded with tyrosine kinase inhibitors, biopolymer implants (like tarcocimab), and potentially even non-invasive oral therapies or specialized eye drops.
- Refined Patient Selection: Clinical experts are now focusing on identifying the "ideal" candidate—typically those who require high-frequency injections or those with mobility and lifestyle constraints that make frequent clinic visits difficult.
Safety Profile
The long-term safety data for the 559 patients in the study provided a clear, manageable profile. Common adverse events included cataracts (27.0%), subconjunctival fibrosis or fluid (13.8%), and vitreous hemorrhage (11.3%). Serious adverse events occurred in 8.1% of the cohort, with conjunctival erosion (2.1%) and endophthalmitis (1.1%) among the most critical, yet rare, complications. These figures have helped specialists refine their surgical techniques, effectively mitigating some of the early-stage risks associated with the device’s introduction.
Conclusion
As the PAGODA trial concludes its latest chapter, the message to the retina community is clear: the ranibizumab port delivery system is a viable, long-term solution for DME patients. By bridging the gap between clinical efficacy and patient quality of life, the PDS provides a template for the next generation of ocular therapies. While surgical risks remain a factor in clinical decision-making, the overwhelming preference from patients and the stability of long-term visual outcomes suggest that the PDS is poised to become a cornerstone of retinal disease management in the coming decade.
